Evidence map›Paper›PMID 24769645›Full record

ArticleBlood cancer journal2014

Distinct roles of class I PI3K isoforms in multiple myeloma cell survival and dissemination.

I Sahin, M Moschetta, Y Mishima, S V Glavey, B Tsang, F Azab, S Manier, Y Zhang, P Maiso, A Sacco and 3 more

Open access · goldAbstract readLetter

In one paragraph

Article in Blood cancer journal, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it

0cells of the map it votes in

8citing papers in PubMed

1.0field-weighted citation impact, top 23% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

Maleimide-substituted 1,4-naphthoquinone flaviolin mimetic (FMMedical oncology (Northwood, London, England) · 2026
Article
Tissue-specific identification of multi-omics features for pan-cancer drug response prediction.iScience · 2022
Article
Pathogenic signaling in multiple myeloma.Seminars in oncology · 2022
Article
Exonic variants in multiple myeloma patients associated with relapsed/ refractory and response to bortezomib regimens.Saudi journal of biological sciences · 2022
Article
Citron Rho-interacting kinase silencing causes cytokinesis failure and reduces tumor growth in multiple myeloma.Blood advances · 2019
Article
Selinexor synergizes with dexamethasone to repress mTORC1 signaling and induce multiple myeloma cell death.Oncotarget · 2018
Article
High throughput chemical library screening identifies a novel p110-δ inhibitor that potentiates the anti-myeloma effect of bortezomib.Oncotarget · 2016
Article
Loss of serum and glucocorticoid-regulated kinase 3 (SGK3) does not affect proliferation and survival of multiple myeloma cell lines.PloS one · 2015
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

I SahinDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

M MoschettaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

Y MishimaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

S V GlaveyDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

B TsangDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

F Azab1] Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA [2] Cancer Biology Division, Department of Radiation Oncology, School of Medicine, Washington University in St Louis, St Louis, MO, USA.

S ManierDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

Y ZhangDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

P MaisoDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

A SaccoDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

A K Azab1] Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA [2] Cancer Biology Division, Department of Radiation Oncology, School of Medicine, Washington University in St Louis, St Louis, MO, USA.

A M RoccaroDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

I M GhobrialDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

Harvard University · USDana-Farber Cancer Institute · US

Funding

The role of miRNA15a and 16-1 in Multiple MyelomaR01CA154648 · NCI · DANA-FARBER CANCER INST · PI GHOBRIAL, IRENE M. · 2011 to 2015

$1.8M

NCI NIH HHS R01 CA154648

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AnimalsCell SurvivalDisease ProgressionGene Knockdown TechniquesHumansIsoenzymesMiceMice, SCIDMultiple MyelomaPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktIsoenzymesPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-akt

Identifiers

PMID24769645

DOI10.1038/bcj.2014.24

PMCPMC4003418

OpenAlexW2124893415

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.